Verastem has opened its KRAS G12D colorectal cancer trial, but the real test is still ahead
Verastem has started TARGET-D 203, testing VS-7375 alone and in combinations for KRAS G12D metastatic colorectal cancer.
Pharma & Biotech
Pharma & Biotech
Why Tempus’ tumor-only xT CDx approval could matter for precision oncology testing
Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.